Translating the MDS flow cytometric score into clinical practice

Myelodysplastic syndromes (MDS) are classified by the WHO as myeloid neoplasms, and are characterized by cytopenia and dysplasia in one or more myeloid cell lines. Recently, a flow cytometric score (FCM‐score) was published capable of discriminating low‐grade MDS from non‐clonal cytopenias (Della Po...

Full description

Saved in:

Bibliographic Details
Published in:	Cytometry. Part B, Clinical cytometry Vol. 88; no. 3; pp. 207 - 209
Main Authors:	Heron, Michiel, Dovern, Elisabeth, Bakker‐Jonges, Liesbeth E., Posthuma, Eduardus F.M., Brouwer, Rolf E., Smedts, Frank, Batstra, Manou R.
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01-05-2015
Subjects:	Antigens, CD - immunology Bone Marrow Cells - classification Bone Marrow Cells - immunology Bone Marrow Cells - pathology flow cytometry Flow Cytometry - statistics & numerical data Hospitals, Teaching Humans immunophenotype Immunophenotyping myelodysplastic syndrome Myelodysplastic Syndromes - diagnosis Myelodysplastic Syndromes - immunology Myelodysplastic Syndromes - pathology Neoplasm Grading Netherlands Precursor Cells, B-Lymphoid - classification Precursor Cells, B-Lymphoid - immunology Precursor Cells, B-Lymphoid - pathology Research Design Sensitivity and Specificity Netherlands myelodysplastic syndrome flow cytometry immunophenotype
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Myelodysplastic syndromes (MDS) are classified by the WHO as myeloid neoplasms, and are characterized by cytopenia and dysplasia in one or more myeloid cell lines. Recently, a flow cytometric score (FCM‐score) was published capable of discriminating low‐grade MDS from non‐clonal cytopenias (Della Porta et al., 2012). We tested the applicability of the FCM‐score in a patient population from a large peripheral teaching hospital in The Netherlands. The evaluation of the proposed FCM score in low‐grade MDS showed a high sensitivity and specificity, and clinically significant positive and negative likelihood ratios. The use of CD10 and CD19 positivity to identify progenitor B‐cell blasts provided a specific and precize method to separate progenitor B‐cell blasts from myeloid blasts within the CD34+/low CD45+ population and may be more convenient compared to the published method using low SSC and CD45 expression. This study confirms the value of utilizing the FCM‐score in our patient population. © 2014 International Clinical Cytometry Society © 2014 International Clinical Cytometry Society
Bibliography:	Author contribution: MH and ED designed and performed the study and/or analysed data. MH and ED wrote the manuscript. LEB, EFMP, REB, FS and MRB provided intellectual input and advice on study design and analysis. Conflict of interest disclosure: The authors have no conflict of interest to declare. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1552-4949 1552-4957
DOI:	10.1002/cyto.b.21208